Related Experiment Video
Updated: May 1, 2026
Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
Impacts of Rivaroxaban on Functional Outcomes in Patients with Lower-extremity Peripheral Artery Disease Following
Seyed Masood Mousavi1, Arman Azmoon1, Iraj Nazari1
1Department of General Surgery, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Background:
Rivaroxaban (RIVA) is a medication with anti-inflammatory and anticoagulant properties that may slow the progression of peripheral artery disease (PAD). This trial evaluated the effects of RIVA on functional outcomes in patients with lower extremity PAD (LEPAD) following endovascular revascularization.
Methods:
A six-month, double-blind, randomized controlled trial was conducted at Golestan Hospital (Ahvaz, Iran) and enrolled patients with LEPAD who had undergone endovascular revascularization within the previous 10 days. Clinical and demographic data were collected from the participants. Participants were randomly assigned to receive either RIVA (2.5 mg twice daily) plus aspirin (80 mg once daily) or clopidogrel (CLOP; 75 mg once daily) plus aspirin (80 mg once daily) for six months.
Results:
The trial enrolled 104 patients with LEPAD. A total of 53 participants were assigned to the RIVA group, while 51 were assigned to the CLOP group. Among the patients, 73 were men, and 41 were women, with a mean age of 68 years. After six months, the RIVA group demonstrated significantly greater improvements in functional outcomes, pain, and claudication symptoms compared to the CLOP group. Notable between-group differences included improvements in the six-minute walk test (6MWT) distance (63.67 ± 1.34 m; p < 0.05), anklebrachial index (ABI) (0.10 ± 0.03; p < 0.05), and toe-brachial index (TBI) (0.08 ± 0.02; p < 0.05).
Conclusion:
RIVA was more effective than CLOP in improving functional outcomes, reducing claudication, and alleviating pain in patients with LEPAD.
Clinical Trial Registration Number:
This trial was registered at irct.behdasht.gov.ir as IRCT20231117060086N1.
More Related Videos
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
06:04Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
Published on: August 8, 2025
